ORKA Stock Q2 2026: Oruka Therapeutics Earnings - A $7.4B Bet On One Drug

Oruka Therapeutics (ORKA) Q2 2026 — Q2 2026 (quarter ended June 30; the 8-K cleared EDGAR 07:00 ET Monday August 10, BEFORE the open, so August 10 IS the reaction session: opened -2.29 pct at USD96.56 and CLOSED +6.40 pct at USD105.14, on 0.68x normal volume. By August 14 it closed USD111.04, a 52-week high.) Oruka is a clinical-stage immunology company with no revenue, no debt and USD1.25B of cash, whose lead antibody ORKA-001 cleared 40 of 63 patients completely at Week 16 in EVERLAST-A. But two headline figures are understated: the release's USD1.1B cash omits a USD122.5M July share sale disclosed only in the 10-Q, and the USD6.70B screen market cap omits 11,428,149 Series B preferred shares. Fixed, the pipeline costs USD7.37B. THE CALL: AVOID (3/5, MEDIUM - GOOD SCIENCE AT A PRICE THE MODEL CANNOT REACH) — base-case value ~$54.31 vs ~$111.04 today. KEY METRICS: - CALL: AVOID, 3/5. Fair value USD54.31 vs the USD111.04 close, -51.1 pct. Risk-adjusted sum-of-parts, every input an ASSUMPTION: peak sales x probability of success x 2.2, discounted 11 pct. BEAR USD19.36, BASE USD45.25, BULL USD97.04, weighted 25/45/30. - THE ANGLE - BOTH HEADLINE NUMBERS ARE UNDERSTATED. The release says cash and securities of USD1.1B at June 30. Only the 10-Q liquidity note adds that in July 2026 Oruka sold 1,499,500 shares for USD122.5M net. Pro forma cash is USD1,248.1M. The release never mentions it. - THE SHARE COUNT: the 10-Q cover says 66,209,699 common at July 31, and 137,138 Series B preferred convert 83.3332:1 into 11,428,149 more. Economic count 77,637,848 = USD8.62B, not the USD6.70B screens print. Enterprise value USD7.37B, not USD5.57B. - THE REVERSE TEST: at USD111.04, ORKA-001 alone must carry USD7.28B of risk-adjusted value - USD11.7B of peak annual sales at 50 pct odds. Skyrizi, the biggest drug in the class, did USD17.562B in 2025 (AbbVie FY25). The Street's USD153.25 needs USD17.0B. - THE QUARTER: R&D USD43.3M (+80 pct, incl a one-time USD5.0M Halozyme upfront), G&A USD6.9M, opex USD50.1M, interest income USD8.9M, net loss USD41.2M, EPS -USD0.55. No warrant or preferred revaluation - other income is USD4 THOUSAND. Pure burn. - RUNWAY IS NOT THE CONSTRAINT: USD1,248.1M against USD56.7M of H1 operating cash use is about 44 quarters. The calendar is: EVERLAST-A Week 28 end-Q3, EVERLAST-B Week 16 Q4, ORKA-004 into clinic Q4, EVERLAST-A 52-week DECEMBER. Cash funds a BLA FILING only. - STACKED THIRD-PARTY ECONOMICS: ORKA-001 and ORKA-002 are licensed in from Paragon Therapeutics, a related party whose board Fairmount appoints. Low single-digit royalty each; Halozyme takes MID single-digit plus USD150.0M of sales milestones; WuXi under 1 pct. What to watch: UP: December 2026 EVERLAST-A 52-week data showing responses hold at six-month dosing intervals, which turns convenience into a label and lifts our 50 pct probability of success; also EVERLAST-B Week 16 across 187 patients in Q4. DOWN: any loss of response between Week 28 and Week 52, or a Phase 3 program that slips past 1H 2027. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision. Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video Educational only. Not financial advice.